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Abstract: Alpha-1-antitrypsin deficiency (AATD), also known as alpha1-proteinase inhibitor 
deficiency, is an autosomal co-dominant condition. The genotypes associated with AATD 
include null, deficient, and dysfunctional alpha-1-antitrypsin (A1AT) variants, which result in 
low levels of circulating functional A1AT, unbalanced protease activity, and an increased risk of 
developing lung emphysema, the leading cause of morbidity in these patients. Furthermore, the 
most common abnormal genotype, Pi*ZZ may also cause trapping of abnormally folded protein 
polymers in hepatocytes causing liver dysfunction. A major focus of therapy for patients with 
lung disease due to AATD is to correct the A1AT deficiency state by augmenting serum levels 
with intravenous infusions of human plasma-derived A1AT. This strategy has been associated 
with effective elevations of A1AT levels and function in serum and lung epithelial fluid and 
observational studies suggest that it may lead to attenuation in lung function decline, particu-
larly in patients with moderate impairment of lung function. In addition, an observational study 
suggests that augmentation therapy is associated with a reduction of mortality in subjects with 
AATD and moderate to severe lung impairment. More recent randomized placebo-controlled 
studies utilizing computer scan densitometry suggest that this therapy attenuates lung tissue 
loss. Augmentation therapy has a relative paucity of side effects, but it is highly expensive. 
Therefore, this therapy is recommended for patients with AATD who have a high-risk A1AT 
genotype with plasma A1AT below protective levels (11 µM) and evidence of obstructive 
lung disease. In this article, we review the published evidence of A1AT augmentation therapy 
efficacy, side effects, and safety profile.
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Introduction
Definition
Alpha-1-antitrypsin deficiency (AATD) is a hereditary autosomal co-dominant condition, 
which occurs from the inheritance of two protease inhibitor deficiency alleles of the 
alpha-1-antitrypsin (A1AT) gene. The A1AT gene, also known as alpha1-proteinase 
inhibitor gene, PI or SERPINA1, spans 12.2 kb on the human chromosome 14q31–32.3 
and encodes a 52-kD single-chain glycoprotein composed of 394 amino acid residues 
and three asparagine-linked complex carbohydrate side chains. Hepatocytes are the 
primary source of A1AT, but other cells including mononuclear phagocytes and lining 
epithelial cells of the intestinal and respiratory tract, also synthesize this protein. A1AT’s 
main function is serine proteinase inhibition. Neutrophil elastase, a 29-kD extracellular 
endopeptidase is the preferred target for A1AT, which baits the proteinase at its active site 
forming a stable 1:1 equimolar complex, which is then cleared from the circulation.1Biologics: Targets & Therapy 2009:3 194
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Prevalence
The AATD prevalence data indicate variable distribution 
around the globe, being highest in northwestern Europe, 
reaching 1:1,600 in Sweden.2 In the US, where the Z genes 
frequencies are highest in individuals of northern and western 
European descent,3 prevalence estimates range from 1: 2,857 
to 1: 5,097.4,5
Abnormal A1AT genotypes
A1AT is a highly pleomorphic protein, reflecting a polymorphic 
gene locus with approximately 100 alleles identified to 
date. Genotype variants are classified according to the 
protease inhibitor (PI) isoelectric focusing electrophoretic 
mobility and to the plasma level and function of A1AT. 
The normal variant includes the common M types, present 
in 95% of Caucasian individuals with normal A1AT plasma 
levels (20 µmol/L). The deficiency variants include the 
more common Z and S variants found predominantly in 
the Mediterranean region as well as the rare “M-like” or 
“S-like” types. These variants are caused by a single amino 
acid mutation and are usually associated with plasma A1AT 
levels  20 µmol/L. The rare “null” variant is associated 
with undetectable A1AT levels. The dysfunctional forms are 
characterized by normal circulating levels of a functionally 
impaired A1AT.6
Pathogenesis of lung and liver  
disease in AATD
The decrease in levels of circulating functional A1AT renders 
organs such as the lung susceptible to the unopposed action of 
activated neutrophil elastase released from inflammatory cells. 
The disrupted homeostasis between protease–antiproteases 
is further augmented by cigarette smoking, which is associ-
ated with excessive elastase activity, degradation of elastin 
in the lung parenchyma, and ultimately development of the 
chronic obstructive pulmonary disease (COPD), emphysema. 
Approximately 60% of individuals with AATD develop 
COPD, suggesting that AATD alone is usually not suffi-
cient to cause emphysema, cigarette smoking being a major 
pathogenic co-factor in these individuals. Recent studies have 
shown that in addition to the classical protease–antiprotease 
imbalance in AATD, there are several other mechanisms 
implicated in the pathogenesis of lung disease in susceptible 
individuals. Oxidants in cigarette smoke have been shown 
to oxidize methionine residues within the A1AT active site 
and weaken its antiprotease function.7 Similarly, the mutant 
Z A1AT, which has a high propensity for forming polymers, 
inhibits neutrophil elastase at a slower rate than M A1AT. 
Furthermore, these polymers exert chemotactic activities,8 
augmenting the neutrophil elastase burden and perhaps 
explaining why individuals with AATD have a larger number 
of neutrophils in the lung parenchyma compared to normal 
individuals.9 In addition, in recent years there was increas-
ing evidence of serpins interacting with enzymes such as 
cathepsins10,11 or caspases12 which uncovered unexpected 
cytoprotective13,14 and antimicrobial15–17 roles to this class 
of molecules. Examples of noncanonical effects of A1AT, 
which we recently summarized,18 include intracellular 
uptake and inhibition of apoptosis of pulmonary vascular 
endothelial cells,12,13,19 direct anti-inflammatory effects on 
immune20,21 and lung vascular cells,22 and effects on alveolar 
and epithelial lung fluid volume regulation.23,24 Impairment 
of these protective mechanisms in AATD may contribute to 
the pathogenesis of lung disease in AATD and may, in the 
future, expand the scope and indications of A1AT augmen-
tation therapy.
In contrast to the pathogenesis of lung disease, the liver 
involvement in AATD is likely due to the trapping and 
accumulation of Z A1AT polymers inside hepatocytes. 
Indeed, individuals carrying the A1AT null genotype lack 
liver involvement. In the case of the Pi*Z, Pi*S, or other 
unstable mutations of A1AT, the abnormally folded protein 
accumulates in the endoplasmic reticulum, leading to liver 
injury, which may culminate in cirrhosis or hepatocellular 
carcinoma in some patients.25 Many AATD individuals 
with Pi*Z remain protected from this gain-of-toxic func-
tion though a protective autophagic disposal of abnormal 
proteins.26
Clinical manifestations
Although most individuals with AATD remain asymptomatic, 
the most common clinical manifestation of this condition is 
COPD, which develops especially in those exposed to ciga-
rette smoking. COPD occurs predominantly in the 3rd–4th 
decade of life and manifests predominantly as emphysema, 
chronic bronchitis, or bronchiectasis, with symptoms such 
as dyspnea, cough, wheezing, inability to exercise, fatigue, 
and frequent respiratory infections.27 The diagnosis is sup-
ported by pulmonary function tests which may reveal airflow 
obstruction (with decreased forced expiratory volume in one 
second [FEV1] and FEV1/forced vital capacity [FVC] ratio) 
and impaired gas exchange. Radiologic examination of the 
lungs by computer tomography (CT) shows decreased attenu-
ation of lung tissue with a predominant basal distribution and 
a panlobular pattern, along with variable degrees of bronchial 
wall thickening and dilatation. The lung involvement may Biologics: Targets & Therapy 2009:3 195
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progress to respiratory failure and death. Since the majority 
of subjects with AATD and lung disease have a history of 
tobacco use and their clinical presentation may be undistin-
guishable from non-AATD-related COPD,28 current guide-
lines recommend AATD testing for all individuals diagnosed 
with COPD.29 The liver is the second most common organ 
involved in AATD, in approximately 10% of individuals 
with this condition. Liver disease occurs predominantly in 
children but also long-term survivors of AATD, manifest-
ing as jaundice and hepatomegaly, which in rare cases may 
progress to hepatic cirrhosis and hepatocellular carcinoma. 
Very infrequent but nevertheless intriguing manifestations 
of AATD are vasculitis30 and the indurated painful skin rash 
of necrotizing panniculitis.31
General treatment considerations  
for AATD
In addition to consideration of A1AT augmentation therapy, 
the overall approach to treating individuals with lung dis-
ease from AATD follows the general principles that apply 
to treating COPD of any etiology,29 including the use of 
bronchodilators and inhaled steroids.32 In general, bron-
chodilators may provide symptomatic improvement even 
in the absence of a documented bronchodilator effect on 
pulmonary function tests. Antibiotics should be provided 
early for COPD exacerbations and long-term oxygen therapy 
should be instituted when indicated. In addition, subjects 
with AATD and emphysema may experience depression and 
anxiety, conditions that should be appropriately addressed 
and treated. Not in the least, subjects with AATD and COPD 
may have significant benefits from participating in disease 
management programs.33
A1AT augmentation therapy  
for AATD
The major goal of the A1AT augmentation therapy in the 
treatment of patients with AATD and lung disease is to 
elevate levels of A1AT in plasma and lung interstitium and 
correct the deficiency state, with the rationale that adequate 
A1AT levels may prevent further lung destruction and halt 
disease progression.29 A1AT augmentation therapy has no 
role in the liver disease due to AATD, as the etiology is 
related to ineffective secretion of A1AT from hepatocytes. 
If these patients develop severe hepatic insufficiency and 
cirrhosis, consideration should be made for orthotopic liver 
transplantation.
The approaches to providing A1AT augmentation 
therapy include systemic delivery of A1AT by intravenous 
or inhalational routes. The intravenous route uses human 
plasma-derived purified preparations and is currently the 
US Food and Drug Administration (FDA)-approved form 
of therapy. The inhalational route, which has been tested 
with both human plasma-derived and recombinant A1AT 
preparations remains experimental.10,34 Still in experimental 
stages are several genetic approaches of A1AT augmentation, 
recently detailed in an excellent review by McLean and col-
leagues.35 Other methods to increase circulating A1AT have 
been described, aimed at enhancing endogenous A1AT pro-
duction and/or secretion with hormonal derivatives such as 
danazol or tamoxifen.36,37 The following discussion will focus 
on intravenous A1AT protein augmentation approach since it 
is the only approved form of therapy currently available.
Biological efficacy of augmentation 
therapy
An effective A1AT augmentation intervention is defined by 
biochemical and clinical criteria.38 To fulfill the biochemical 
criteria of efficacy, there should be evidence that intravenous 
augmentation therapy raises A1AT serum levels above the 
protective threshold and does so over the entire inter-dose 
interval, coupled with evidence that the functional capacity 
of infused pooled human plasma A1AT to oppose neutrophil 
elastase is preserved after its administration. These criteria 
were met by weekly infusions of purified human A1AT 
(60 mg/kg), which kept serum A1AT levels above 11 µM.39 
This dosing regimen increased local A1AT levels in the lungs, 
documented by a 60% to 70% elevation in the antineutrophil 
elastase capacity of the epithelial lining fluid obtained via 
bronchoalveolar lavage.39 The serum threshold used in this 
study was derived from epidemiological studies that associ-
ate levels below 50 mg/dl (11 µM) with an increased risk of 
emphysema, levels of 50–80 mg/dl with an uncertain risk, and 
levels above 80 mg/dl with no risk of lung disease. Further-
more, the weekly dosing of 60 mg/kg was chosen based on 
the serum half life of A1AT, its estimated volume of distri-
bution, and prior infusion experiences.40 To date, this dosing 
protocol and A1AT threshold remain the recommended goals 
of intravenous A1AT augmentation therapy.29
In order to gauge the efficacy of A1AT augmentation 
therapy, in addition to antielastase activity of the airway lin-
ing fluid, there is an active research effort to identify other 
biomarkers which would be pertinent to the lung involve-
ment in AATD. The pathogenesis of lung function decline 
in COPD in general and AATD in particular is complex and 
involves increased matrix proteolysis and destruction of 
lung units. Gottlieb and colleagues measured the effect of Biologics: Targets & Therapy 2009:3 196
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exogenous A1AT (60 mg/kg once a week for eight weeks) 
on urine desmosine, a marker of lung matrix degradation, 
in 12 subjects with AATD (serum A1AT of 17–69 mg/dl).41 
During treatment, the mean urinary excretion of desmosine 
remained unchanged from its high baseline levels (p = 0.85), 
suggesting that elastin degradation was not dependent upon 
neutrophil elastase at this stage of the disease, at least in this 
small group of subjects. Similar results were obtained in a 
study comparing two different commercial preparations of 
A1AT, in which neither preparation lead to a statistically 
significant decrease in urine desmosine excretion at 12 weeks, 
compared to levels obtained prior to the start of augmentation 
therapy.42 Further studies are needed to increase our insight 
on how A1AT affects the pathogenesis of COPD, espe-
cially in light of the discovery of noncanonical functions of 
this protein.
Clinical efficacy of augmentation therapy: 
Observational studies
Although the strongest evidence of clinical efficacy of any 
form of therapy is gained through randomized, placebo-
controlled studies, execution of such studies in AATD indi-
viduals has been faced with multiple challenges, including 
ethical dilemmas of placebo use and difficulty to enroll a 
sufficient number of subjects. Therefore, most of the initial 
clinical efficacy studies of augmentation therapy had relied 
on nonrandomized prospective observational approaches that 
included as a main outcome the changes in lung function 
decline measured by spirometry (ie, rate of FEV1 decline 
over time) (Table 1).
The earliest study by Seersholm and colleagues in 199738 
was a prospective controlled, nonrandomized trial comparing 
198 German subjects with AATD who were treated with a 
weekly A1AT dose of 60 mg/kg IV versus 97 Dutch subjects 
with AATD patients who received no A1AT infusions. All 
patients were ex-smokers, with PI ZZ genotype, A1AT 
plasma levels below 11 µM and lung emphysema. After 
4.5 years of follow-up, there was a statistically significant 
slower decline in lung function in the treated group compared 
with the untreated group (decline in FEV1 = 53 ml/year versus 
75 ml/year, respectively, p = 0.02). Stratification by initial 
lung function showed an effect of treatment primarily for 
patients with an FEV1 = 31%–65% predicted, the range of a 
moderate obstructive ventilator defect.38 Therefore, the study 
indicated that augmentation therapy may slow the disease 
progression in patients with moderately reduced lung func-
tion due to AATD.
The largest prospective cohort study in the USA was 
conducted by the National Heart Lung and Blood Institute 
(NHLBI) AATD Registry Group, which analyzed data from 
individuals with severe AATD in 1998.43 The study included 
1129 subjects, and analyzed data from 927 subjects, of which 
277 were untreated versus 650 treated with A1AT augmenta-
tion therapy (of those, 389 were always treated and 261 were 
only partly treated). All subjects were 18 years or older and 
had A1AT levels  11 µmol/L. Over a follow-up period of 
3.5 years, subjects receiving A1AT augmentation therapy had 
a lower mortality rate compared to the untreated group (risk 
ratio [RR] = 0.64, 95% [CI]: 0.43–0.94; p = 0.02), particularly 
in subjects with FEV1  50% predicted. Overall there was 
no statistically significant difference in the decline in FEV1 
between the treated and the untreated group, but in patients 
with moderate airflow obstruction (mean FEV1 = 35%–49% 
predicted) the decline in lung function was significantly 
slower for subjects receiving augmentation therapy (mean 
difference = 27 ml/year, 95% CI: 3–51 ml/year; p = 0.03). 
The main limitations of this study were that the decision to 
treat was left to the primary treating physician and the A1AT 
dosing regimens varied among treated subjects.
A third study investigated the rate of lung function 
decline before and after the initiation of A1AT augmen-
tation in a cohort of 96 German patients with AATD.44 
Table 1 Comparison of changes in Fev1 decline in prospective observational studies of augmentation therapy
Study Overall changes in FEV1 decline Changes in FEV1 decline in specific subgroups
  With  
augmentation
Without 
augmentation
P  Initial FEV1  With 
augmentation
Without 
augmentation
P 
Seersholm and colleagues32 53 ml/yr 75 ml/yr 0.02 31%–65% 62 ml/yr 83 ml/yr 0.04
NHLBi35 51 ml/yr 56 ml/yr NS 35%–49% 66.4 ml/yr 93.2 ml/yr 0.03
wencker and colleagues36 34.2 ml/yr 49.2 ml/yr 0.019 30%–65% 37.8 ml/yr 49.3 ml/yr NS
65% 48.9 ml/yr 122.5 ml/yr 0.001         
Chapman and colleagues37 30 ml/yr 63 ml/yr 0.019 NS      
Abbreviations: Fev1, forced expiratory volume in one second; NS, not significant.Biologics: Targets & Therapy 2009:3 197
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The group included subjects with A1AT levels  35% of 
normal, regardless of phenotype and moderate obstruc-
tive lung disease (FEV1  65% predicted). In addition, 
subjects with accelerated lung function decline (FEV1 
decline rate 120 ml/year) were included, regardless of base-
line FEV1. The study showed that the decline in FEV1 was 
significantly slower during the treatment period compared to 
the pre-treatment period (34.3 ml/year versus 49.2 ml/year, 
respectively; p = 0.019). A subset analysis showed that 
augmentation therapy was particularly effective in patients 
with baseline FEV1  65% predicted (mean difference 
73.6 ml/year; p = 0.045), and in seven individuals who exhib-
ited a rapid decline in FEV1 before beginning augmentation 
therapy (256 ml/yr versus 53 ml/year; p = 0.001). There was 
also a trend for a statistical significant (p = 0.066) effect of 
augmentation therapy in slowing the rate of FEV1 decline in 
patients with moderate airflow obstruction at baseline (FEV1 
30%–65% predicted).
Finally, a retrospective observational study using data 
collected by the Canadian AIR Registry, compared 21 subjects 
receiving augmentation therapy versus 42 matched controls, 
followed for 5.6 years. The results of this study, reported as 
an abstract, suggested a slower decline in FEV1 in patients 
receiving augmentation therapy compared with the subjects 
who did not (29.9 ml/yr versus 63.6 ml/year; p = 0.019).45
Together, all these observational studies strongly suggest 
that A1AT augmentation therapy slows the decline in lung 
function in subjects with A1AT and lung disease, particularly 
in those with a moderate severity of airflow obstruction.
Clinical efficacy of augmentation therapy: 
randomized studies
The observational studies discussed above provided useful 
information for the design of subsequent prospective placebo-
controlled studies. For example, using the rate of FEV1 
decline as the primary outcome and based on the NHLBI 
Registry study data, to detect a difference in FEV1 decline 
of 23 ml/yr (ie, a 28% reduction), a study would require an 
enrollment of 147 subjects per treatment arm, with an initial 
FEV1 of 35% to 49% predicted, and who will undergo bian-
nual spirometry measurements over a four-year period.46 
Similarly, a study to detect a 40% reduction in mortality over 
a five-year period would require 342 subjects per treatment 
arm.46 Furthermore, there are other major challenges in con-
ducting such trials, including the caveat of FEV1 use as main 
outcome in COPD trials, criticized due to its poor correlation 
with the extent of emphysema and other important outcomes 
such as health-related quality of life;47 the variable rate of 
lung disease progression; and the often delayed clinical 
diagnosis of individuals with AATD.28,44
A more recent method in COPD research is the use of CT 
scanning to assess lung density, an outcome which strongly 
correlates with quantitative pathology scores of emphysema 
and is more sensitive to detect progression of emphysema 
compared to traditional lung function parameters.48 Dirksen 
and colleagues reported the first double blind, randomized 
placebo-controlled trial of A1AT augmentation therapy, 
using both FEV1 and CT-measured lung densitometry as 
outcomes.49 They compared the effect of 250 mg/kg of A1AT 
against 625 mg/kg of albumin administered at four week 
intervals for at least three years in 56 patients with AATD 
and moderate obstructive ventilatory defect (FEV1 30%–80% 
predicted). Admittedly underpowered for both outcomes, no 
differences were noted in the FEV1 decline, but there was a 
trend for a reduction in the loss of lung tissue in the group 
who received A1AT augmentation therapy compared to the 
placebo group (1.5 ± 0.41 g/L/year versus 2.6 ± 0.41 g/L/year 
(mean ± SEM), respectively (p = 0.07).49
A more recent European trial (The EXAcerbations and 
CT scan as Lung Endpoints [EXACTLE] trial) further 
explored the use of CT densitometry for the assessment of 
a conventional regimen of augmentation therapy in subjects 
with AATD and lung disease. The study included 77 patients 
with AATD and PiZ who were randomized to receive either 
A1AT augmentation therapy (60 mg/kg IV weekly) or 
placebo for 2–2.5 years.50 Similarly to their previous trial, 
the patients who received A1AT had a trend towards lesser 
decline in lung density measurements (Table 2). This trial 
also supports the notion that CT densitometry may be more 
sensitive in detecting changes in response to treatment com-
pared to other functional and subjective parameters in sub-
jects with emphysema and AATD.50 Indeed, a higher powered 
multinational randomized placebo-controlled trial is utilizing 
CT densitometry as primary outcome of A1AT augmentation 
therapy in AATD (clinicaltrials.gov # NCT00261833).
Augmentation therapy: effect 
on exacerbations
The effect of A1AT augmentation therapy on airway 
inflammatory markers was evaluated by Stockley and 
colleagues in 12 subjects with AATD and Pi Z before and 
following A1AT augmentation therapy (60 mg/kg weekly 
for four weeks).51 Augmentation therapy led to a rise of 
AAT concentration in sputum similar to that of nondeficient 
subjects. Furthermore, A1AT augmentation was associated 
with a favorable change in the sputum inflammatory milieu, Biologics: Targets & Therapy 2009:3 198
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with statistical significant reductions in sputum elastase 
activity and levels of the chemoattractant leukotriene B4, 
and a trend towards decreased sputum myeloperoxidase and 
interleukin-8.
In addition to decreasing airway inflammation, other 
endpoints of efficacy of augmentation therapy investigated 
in the setting of respiratory exacerbations were the rate of 
airway microbial colonization and the frequency of acute 
COPD exacerbations in AATD. Lieberman and colleagues 
conducted a patient survey to document the self-reported 
sense of personal benefit from augmentation therapy.52 Of 
the adult patients with Pi ZZ genotype interrogated by a web-
based questionnaire, there were 96 patients who reported 
treatment with A1AT for one year or more and 47 responders 
who reported not receiving such treatment. Seventy-four of 
89 patients who had received infusions for longer than one 
year believed they had definitely benefited from such therapy, 
approximately half of them attributing it to a reduction in the 
number of infectious COPD exacerbations, from a reported 
average of five episodes to less than one episode annually 
(p  0.001). Other prospective studies have shown that such 
acute exacerbations in subjects with AATD are common53 
even with the use of augmentation therapy.28,54 The recently 
reported EXACTLE trial did not show an effect of A1AT 
augmentation therapy on the number of COPD exacerbations 
compared to placebo, but showed that augmentation therapy 
decreased the severity of such acute exacerbations.50 This 
effect which may have a positive impact on health-related 
quality of life, health care utilization, and disease progression 
attributed to reductions in neutrophil elastase burden.
A1AT augmentation treatment 
recommendations
A1AT augmentation therapy is recommended for individuals 
with abnormal A1AT genotypes who have A1AT levels 
below the protective threshold of 11 µM and have evidence 
of airflow obstruction.29 Since weekly infusions of AAT at 
60 mg/kg are effective in restoring plasma AAT concentra-
tions to protective levels and restoring the epithelial lung 
fluid’s antielastase properties throughout the dosing interval, 
regulatory agencies and guidelines have thus recommended 
this schedule and dosing for the treatment of affected 
individuals.29
Dosage and frequency considerations
Since augmentation therapy is expensive, it is imperative 
to optimize its utilization, particularly since costs have not 
decreased despite the advent of more suppliers on the market 
in recent years. Considerations for optimal dosage and infu-
sion schedules include patient’s comfort and acceptance, as 
well total treatment costs. In fact, the recommended regimen 
of 60 mg/kg once a week has not been widely adopted. In the 
Table 2 Changes in emphysema progression assessed by computed tomography densitometry in placebo-controlled studies of 
augmentation therapy
Study Design N Augmentation  
therapy
Placebo Estimated treatment differences  
(augmentation–placebo)
P value 
             Method  Result 
(g/L/year)
  
Dirksen 143 Double-blind,  
randomized  
placebo-controlled  
(two centers)
56 250 mg/kg iv every four 
weeks for three years
Albumin (625 mg/kg) 15th percentile  
lung density (PD15)  
adjusted for lung  
volume (g/L)
8.9 
(2.6–11.5)
0.07
Dirksen 2  
(eXACTLe)44
Double-blind,  
randomized  
placebo-controlled  
(three centers)
77 60 mg/kg iv every week 
For 2–2.5 years
albumin (2%) Method 1a 
(physiological, slope  
analysis)
0.857 
(-0.065–1.778)
0.068
Method 2 (statistical,  
slope analysis)
0.700 
(-0.028–1.427)
0.059
Method 3  
(physiological,  
end-point analysis)
1.596 
(-0.220–3.412)
0.084
           Method 4 (statistical,  
end-point analysis)
1.472 
(0.009–2.935)
0.049 
Notes: aAnalyzed 15th percentile lung density (density value at which 15% of the pixels have lower densities) using two methods of adjustment for lung volume variability 
(physiological and statistical) and two statistical approaches (slope analysis and end-point analysis).Biologics: Targets & Therapy 2009:3 199
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NHLBI study, 25.3% of participants received biweekly 
and 21.8% received monthly infusions at the beginning of 
the study with additional patients switching to non-weekly 
regimens during the study period.55 In a more recent study 
of 922 patients, 32.4% received infusions every two weeks 
and 7.6% received monthly infusions.54
Initial studies addressing the biological efficacy of 
non-weekly regimens suggested that there was only partial 
coverage throughout the dosing interval. For example, 
in nine subjects who received A1AT at 250 mg/kg every 
28 days, serum AAT levels as well the antielastase activity 
in epithelial lining fluid were in the protective range for “at 
least” 25 days after the infusion.56 In another study, a regimen 
of 120 mg/kg every two weeks studied in 23 patients could 
not maintain nadir serum levels above 70 mg/dl for the 
entire 14-day dosing interval in most and did not correlate 
with adequate antielastase activity in epithelial lining fluid 
assessed by bronchoscopy.57 However, studies directly 
comparing clinical outcomes with these nonweekly regimens 
are not available and in the NHLBI study it was observed 
that the initial frequency of therapy was not associated with 
differences in survival.55
Pharmacokinetic considerations
A high level of variability in trough serum A1AT levels in 
response to dosing has been observed in several studies, rais-
ing the concept that targeted pharmacokinetic studies may 
lead to the design of individualized dosing regimens. In the 
first of these studies, daily A1AT levels were followed in 
five patients after receiving a dose of 120 mg/kg of A1AT 
and were used to calculate individual dosage schemes with 
a computer simulation using a two-compartment pharmaco-
kinetic model.58 The authors estimated that a dose of 1–2 g 
every two weeks should be enough to maintain trough A1AT 
levels above the protective threshold in most individuals, 
a dose markedly lower than the recommended 60 mg/kg/
week. In another study, Monte Carlo simulations based on 
population pharmacokinetic concepts applied to A1AT levels 
measured after weekly, bi-weekly, tri-weekly, and monthly 
dosage regimens, showed that intervals between infusions 
longer than one week are possible in most patients while 
maintaining an appropriate level of serum AAT above the 
protective threshold (50 mg/dl).59 In this study, the authors 
proposed that a tri-compartment model is more suitable for 
exogenous AAT administration and suggested that weekly 
doses of 50 mg/kg or bi-weekly doses of 120 mg/kg confer 
protective trough levels at least 85% of the time, while a 
monthly regimen is not suitable, as it protected for only 22 of 
the 28 days. In a more recent study, Zamora and colleagues 
evaluated seven patients initially receiving 180 mg/kg of 
AAT every three weeks, and used A1AT levels measured 
after 7, 14, and 21 days to readjust dose and frequency based 
on a one-compartment model.60 The authors concluded that 
the mean optimized final A1AT dose was 123.1 mg/kg every 
two weeks (range 118.5–125.6) for a desired AAT serum 
trough of 0.50 g/L. Surprisingly, results differed when two 
different commercial preparations were compared.
In all studies, the once-a-week regimen showed adequate 
protective levels throughout the infusion interval, and this 
has been the regimen studied in most clinical trials including 
the recent randomized studies. The factors associated with 
increased clearance of A1AT have not been defined. Indepen-
dent variables such as sex, age, and body weight have no influ-
ence on pharmacokinetic parameters.60 Although these studies 
suggest that less expensive and more convenient individualized 
regimens can be designed, caution should be employed, since 
clinical outcome studies using these personalized regimens 
are not available. If a nonweekly regimen is chosen to treat an 
individual patient, it would be prudent to periodically follow 
trough A1AT levels to ensure adequate protection.
Augmentation treatment 
for heterozygous individuals
Studies have shown that PI*MZ individuals may have a small 
increase in lung function decline (25 ml/yr versus 21 ml/yr)61 
and may have a slightly higher risk for developing COPD 
(odds ratio 2.3)62 compared to PI*MM individuals. It is likely 
that some PI*MZ individuals may have a particularly high 
risk for COPD, however early identification of this subgroup 
is rarely possible. As mentioned before, current augmentation 
therapy strategies aim at increasing A1AT levels above a 
protective threshold, usually lower than what is observed in 
carriers of abnormal A1AT alleles, particularly PI*MZ indi-
viduals. Given the complete absence of any data suggesting 
efficacy for heterozygous individuals, current recommenda-
tions do not endorse use of augmentation therapy for such 
individuals.63 Individuals with PI*SZ genotypes may have 
A1AT levels  11 µM; in such cases, augmentation therapy 
may be advisable if lung function impairment is present.
Safety of intravenous A1AT 
augmentation therapy
The experience of thousands of individuals treated with 
A1AT augmentation therapy suggests that it is generally safe. 
The few side effects reported were generally mild and rarely Biologics: Targets & Therapy 2009:3 200
Petrache et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
required major interventions or interruption of therapy. Two 
major registry studies provide data from large number of 
patients from both Europe and the US.
Wencker and colleagues reported the side effects associ-
ated with augmentation therapy (60 mg/kg IV once a week) 
in 443 patients with severe AATD and emphysema from 
the German registry recruited between 1989 and 1995.64 
Between 1989 and 1995, a total of 58,000 infusions were 
administered which only triggered 124 side effects reported 
in 65 patients. In the majority of these patients the observed 
adverse reactions were typical of intravenous infusions of 
proteins, such as fever or chills (in 17 patients), urticaria 
(18), nausea or vomiting (21), and fatigue (7). Increased 
dyspnea of unclear etiology was reported by 17 patients and 
was thought to be related to the absolute protein load in the 
infusion. Three patients terminated the treatment permanently 
because of repeated symptoms of fevers or chills immediately 
after each infusion from different batches on more than one 
occasion. There were five severe side effects reported during 
the study that required medical intervention or hospitaliza-
tions. Four patients suffered anaphylactic reaction and one 
patient developed congestive heart failure exacerbation, all 
eventually experiencing complete recovery. No deaths or 
viral transmission related to A1AT augmentation therapy 
was observed during the study period.
In the US, the most comprehensive report or side effects 
following A1AT augmentation therapy was published by 
Stoller and colleagues using the NHLBI Registry data.65 
Patients included were divided into “always, sometimes, 
and never receiving therapy”. For all participants and all 
severity categories, the absolute frequency of adverse 
events was very low (95% CI: 0.019 to 0.023 events per 
patient-month), and interestingly, there was no change over 
time in the percentage of participants reporting an adverse 
reaction. A total of 720 side effects were reported, the most 
common ones being headache (47%), dizziness (17%), 
nausea (9%), and dyspnea (9%), the latter being classified 
as severe. No transmission of viral hepatitis, HIV infection, 
or prion disease was reported. Participants receiving weekly 
treatments did report a higher rate of total adverse events 
(0.030 events per patient-month) than those being treated 
every two to three weeks (0.024 events per patient-month; 
p = 0.020) or monthly (0.005 events per patient-month; 
p  0.001). Furthermore, those treated weekly also reported 
statistically significant higher rates of severe and moderate 
adverse events, while subjects who received infusions every 
two to three weeks reported milder adverse effects than 
the other groups. Careful examination of the side effects 
reported from the German registry compared to the US 
registry suggests there were more cases of anaphylactic 
reactions in the European study (four patients versus none, 
respectively), while side effects requiring medical attention 
such as emergency room visit, hospitalization, or physician 
office visit were more common among American patients 
(1% versus 6%, respectively). These differences may be 
due to recall bias (as the side effects in both studies were 
recorded at various time intervals), the exclusion of events 
related to recalled flawed lots (due to the sucrose component 
in one instance and presence of a pyrogen in the other), as 
well as the variable frequency of augmentation therapy in 
the latter study. A rare case of IgE-mediated anaphylactic 
reaction following the third intravenous infusion of A1AT 
has been reported.66
Alpha1-proteinase inhibitor preparations
There are currently three FDA-approved preparations of 
A1AT purified from human plasma commercially available in 
the US: Aralast NP (initially named Respitin and marketed as 
Aralast by Baxter Healthcare; Deerfield, IL, USA), Prolastin 
(Talecris Biotherapeutics, Research Triangle Park, NC, USA) 
and Zemaira® (CSL Behring, King of Prussia, PA, USA). 
All these products are available as lyophilized preparations. 
A liquid preparation (Respira, Kamada Ltd., Israel) as well 
as a purified formulation of Prolastin are planned for future 
release.
Few studies have compared the effectiveness and safety 
between these formulations, with studies showing that 
Aralast42 and Zemaira®67 have biochemical equivalence to 
their comparator, Prolastin. One internally funded pilot 
study from the maker of Zemaira® (Bioanalytical Laboratory, 
Technical Operations, ZLB Behring LLC, Kankakee, IL, 
USA) suggested a higher purity of their product compared 
to Prolastin and Aralast.68
Cost effectiveness of intravenous 
augmentation therapy
A1AT augmentation therapy is expensive, with an aver-
age annual total health care cost ranging from $36,471 to 
$46,114, and a median ranging from $12,485 to $37,100.69,70 
The cost and cost-effectiveness of A1AT augmentation 
therapy (Table 3) is generally analyzed as the cost per life-
year saved (CLYS) for treated individuals, which is the ratio 
of the change in expected net COPD medical cost resulting 
from A1AT replacement therapy relative to the change 
in years of life saved through the intervention. Utilizing 
this method, an initial cost-effectiveness estimation based Biologics: Targets & Therapy 2009:3 201
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on available studies before 1991 by Hay and colleagues 
suggested that to be comparable to widely used medical 
interventions such as antihypertensives, coronary bypass, 
and cholesterol-lowering drugs, A1AT augmentation therapy 
would need to narrow the age- and sex-adjusted survival 
probability gap between Pi ZZ and normal individuals by 
at least 30%–50%.71
Utilizing the declining exponential approximation of life 
expectancy (DEALE) technique, which assumes constant 
death rates and an inverse relation between remaining life 
expectancy and annual death rate, Alkins and O’Malley 
calculated the incremental cost (the value added to usual 
care) per year of life saved (CYLS) for A1AT replacement 
therapy. For a replacement regimen of weekly IV infusions 
of 60 mg/kg in a 70-kg subject with severe AATD and an 
FEV1  50% of predicted, and utilizing mortality data from 
the NHLBI Registry, the CYLS was $13,971. Based on this 
study, it was suggested that A1AT augmentation therapy 
was cost-effective in patients with AATD and emphysema 
with a significant degree of lung dysfunction.72 These 
studies indicated the cost-effectiveness ratio for A1AT 
augmentation therapy was in a similar range with that of 
hemodialysis.
A re-examination of the cost-effectiveness of A1AT 
augmentation therapy using a model of disease progres-
sion also based on data from the NHLBI registry was 
reported by Gildea and colleagues.73 The authors used a 
Markov-based decision analytic module and assessed three 
different strategies: (1) no augmentation therapy for indi-
viduals with AATD; (2) A1AT augmentation therapy for 
life for AATD individuals who have indication for such 
therapy; and (3) A1AT augmentation therapy for AATD 
individuals who have indication for such therapy but only 
until their lung function deteriorates to a FEV1 below 35% 
of predicted. A hypothetical cohort of 30,000 identical 
individuals was evaluated for each strategy using Monte 
Carlo simulation. Costs were adjusted to the 2001 US dol-
lar, and effectiveness was adjusted by quality-adjusted life 
year (QALY). Compared to the individuals with AATD 
and lung disease receiving no augmentation therapy, which 
would incur a $92,091 cost with 4.62 QALYs, the model 
of the AATD individual receiving augmentation treatment 
for life cost $895,243 yielding 7.19 QALYs, while the ones 
receiving augmentation only until FEV1 falls below 35% 
had a predicted cost of $511,930 and produced 6.64 QALYs. 
Therefore, the incremental cost-effectiveness ratio (ICER) 
was $207,841/QALY for an A1AT augmentation therapy 
until FEV1  35% predicted and $312,511/QALY for 
A1AT augmentation therapy for life. It was concluded that 
the annual cost of A1AT augmentation therapy would have 
to be reduced from $54,765 to $4,900 for the augmentation 
therapy for the life strategy to be considered cost-effective. 
Given the lack of alternative treatments, this study further 
emphasized the need to discover both clinically effective 
and cost-effective therapies for individuals with AATD and 
lung disease.
Future considerations
A1AT augmentation therapy  
via aerosol inhalation
The vast area available for gas exchange in the lung has 
long been recognized as an attractive route of systemic drug 
delivery.74 Small studies have demonstrated that aerosolized 
Table 3 Comparison of cost-effectiveness analyses of A1AT augmentation therapy
Study Year Location Method Results Conclusions
Hay and colleagues32 1991 US CLYS CYLS = $28,000–$72,000 for 
70% efficacy. CYLS = $50,000 
and $128,000 for 30% efficacy
Therapy would need to 
improve survival by 30%–50% 
to be cost effective
Alkins and O’Malley72 2000 US AATD 
NHLBi 
registry
DeALe CYLS = $10,747 to $53,735 
for 55% efficacy
Cost effective in those 
with emphysema and lung 
dysfunction
Gildea and colleagues73 2003 US AATD 
NHLBi 
registry
Markov  iCer = $207,841/QALY for 
treatment up to Fev1  35% 
predicted 
iCer = $312,511/QALY for 
treatment for life
Cost should be reduced to 
$4,900 for therapy to be 
considered cost effective 
Abbreviations:   A1AT, alpha-1 antitrypsin;   AATD, alpha-1 antitrypsin deficiency; CYLS, cost per year of life saved; DEALE, declining exponential approximation of life expectancy; 
Fev1, forced expiratory volume in one second; ICER, incremental cost-effectiveness ratios; NHLBI, National Heart Lung and Blood Institute; QALY, quality-adjusted life-year; 
US, United States.Biologics: Targets & Therapy 2009:3 202
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A1AT delivery led to significant elevations of A1AT above 
protective levels in both plasma and the epithelial lining 
fluid,75 which may be translated into sustained antielastase 
protection with once-or twice a day inhalation. In patients 
with AATD and relatively mild lung function impairment, 
adequate deposition of A1AT in the lung periphery appears 
to be achievable using the inhalation route.76 This attractive 
form of therapy, likely to prove less costly than intravenous 
augmentation, is currently under investigation.
Augmentation therapy post lung 
transplantation
Lung transplantation is indicated for subjects with AATD 
and end-stage emphysema. In general, routine post transplant 
augmentation therapy is not recommended, as no supportive 
data are available. However, given the detection of significant 
increases in elastase activity in the lung, as measured in the 
bronchoalveolar lavage of post-transplant patients during 
symptomatic respiratory episodes,77 many clinicians advocate 
the use of A1AT augmentation therapy during episodes of 
lung inflammation, including chronic rejection.78
Conclusions
Current evidence based on prospective observational studies 
suggests that A1AT intravenous augmentation therapy has a 
positive impact in attenuating the lung function decline and may 
decrease mortality in subjects with AATD and moderate air-
flow obstruction. Newer randomized trials suggest that A1AT 
augmentation therapy slows emphysema progression and 
ameliorates the severity of acute disease exacerbations. These 
effects are supported by biochemical evidence that infused 
A1AT reaches the epithelial lung fluid and decreases airway 
inflammation. Experience with intravenous augmentation 
therapy suggests that it is safe, with few and usually well toler-
ated side effects. The decision to initiate augmentation therapy 
in affected individuals with impaired lung function should be 
based on collective data of efficacy, safety of augmentation 
therapy, and, currently, lack of alternative interventions.
Adequately powered randomized, placebo-controlled tri-
als, utilizing clinical and biochemical endpoints of efficacy 
are needed to determine the most effective augmentation 
regimen and the subgroups of patients who would benefit 
from it. Other important issues to be addressed include the 
improvement of the cost effectiveness of therapy, imple-
mentation of alternate modalities of A1AT delivery, and 
further studies to assess the role of augmentation therapy 
after lung transplantation. New insights from basic science 
research regarding novel functions of A1AT and additional 
mechanisms of disease development in AATD, accelerated 
progress in the translational application of gene therapy and 
safe drug delivery, together with ongoing efforts of early 
disease detection, will undoubtedly improve the quality and 
length of life of individuals with this condition.
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